The collaboration covers Evotec’s entire drug discovery offering, including its expertise in medicinal chemistry, biology and compound sourcing. Specifically, this includes biochemical and cellular assay development and high content screening on interesting cell lines with the aim of identifying novel starting points for medicinal chemistry programs. In addition, Evotec supplies key support in the area of medicinal chemistry and supporting biology optimization on multiple biological targets that are of high importance for the treatment of Huntington’s disease.
Mark Ashton, executive vice president of business development services at Evotec, said: “Working together, Evotec and CHDI have the tools in place to rapidly discover novel drugs against Huntington’s disease targets.”